Search This Blog

Wednesday, May 31, 2023

Sanofi: Positive Phase 2 data of MS antibody

 

  • Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placebo

  • Sanofi plans to initiate pivotal trials in multiple sclerosis in early 2024

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)